Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial
Abstract Somatic symptoms are often important in the treatment of major depressive disorder (MDD). The aim of this open-labeled trial was to examine the efficacy of mirtazapine for the treatment of MDD with clinically significant somatic symptoms, as compared with venlafaxine. A total of 126 patient...
Gespeichert in:
| Veröffentlicht in: | Psychiatry research 2009-09, Vol.169 (2), p.118-123 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 123 |
|---|---|
| container_issue | 2 |
| container_start_page | 118 |
| container_title | Psychiatry research |
| container_volume | 169 |
| creator | Kang, Eun-Ho Lee, In-Soo Chung, Sang-Keun Lee, Sang-Yeol Kim, Eui-Jung Hong, Jin-Pyo Oh, Kang-Seob Woo, Jong-Min Kim, Seonwoo Park, Joo-Eon Yu, Bum-Hee |
| description | Abstract Somatic symptoms are often important in the treatment of major depressive disorder (MDD). The aim of this open-labeled trial was to examine the efficacy of mirtazapine for the treatment of MDD with clinically significant somatic symptoms, as compared with venlafaxine. A total of 126 patients with MDD (score ≥ 18 on the Hamilton Rating Scale for Depression-17) were included in both the intent-to-treat ( n = 73 in the mirtazapine group and n = 53 in the venlafaxine group) and completer analysis ( n = 51 and n = 37, respectively). After treatment, both treatment groups showed similar improvements in depressive symptoms. Repeated measures analysis of variance for the intent-to-treat population revealed that there were no significant differences in mean change of the Symptom Check List-90-Revised (SCL-90-R) somatization subscores between the two groups. For completers, there was a significant time × treatment interaction in the SCL-90-R somatization subscores, but the differences between the two groups at endpoint did not reach statistical significance in post-hoc analysis. In conclusion, this study suggests that overall efficacies of mirtazapine and venlafaxine are similar for the treatment of overall symptoms in MDD, and both drugs may be useful for the treatment of somatic symptoms in MDD patients. |
| doi_str_mv | 10.1016/j.psychres.2008.06.021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67638211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165178108001893</els_id><sourcerecordid>67638211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-8997a453c3ae7f743bcf8605a4f7fa1fc36f1422733d070eda72ba1ce5c474953</originalsourceid><addsrcrecordid>eNqFks9u1DAQxiMEoqXwCpUvcCKLHSdxwgG1qvgnFXEAztasPdZ6SeLg8S5sn4JHxtEuIHHhNNLo982Mvm-K4lLwleCifbFdzXQwm4i0qjjvVrxd8UrcK85Fp6pSiUreL84z2JRCdeKseES05Twjff-wOBN92zdKiPPi5wcfE9zB7Cdke4y0o1ymARz8WFouRJY2yFJESCNOiQXHKIyQvGF0GOcURmJAFIyHhJZ992nDRthmncU530d-j8x6CtFifMmuWYTJhtHfoX3OwoxTOcAahyxN0cPwuHjgYCB8cqoXxZc3rz_fvCtvP759f3N9W5q6Eans-l5B3UgjAZVTtVwb17W8gdopB8IZ2TpRV5WS0nLF0YKq1iAMNqZWdd_Ii-LZce4cw7cdUtKjJ4PDABOGHelWtbKrhMhgewRNDEQRnZ6jHyEetOB6yUJv9e8s9JKF5q3ORmfh5WnDbj2i_Ss7mZ-BpycAyMDgsjHG0x8uZ6WatllOvTpymP3Ye4yajMfJoPURTdI2-P_f8uqfEWbwk89bv-IBaRt2ccpua6Gp0lx_Wj5neRzecS66XspfphLEDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67638211</pqid></control><display><type>article</type><title>Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kang, Eun-Ho ; Lee, In-Soo ; Chung, Sang-Keun ; Lee, Sang-Yeol ; Kim, Eui-Jung ; Hong, Jin-Pyo ; Oh, Kang-Seob ; Woo, Jong-Min ; Kim, Seonwoo ; Park, Joo-Eon ; Yu, Bum-Hee</creator><creatorcontrib>Kang, Eun-Ho ; Lee, In-Soo ; Chung, Sang-Keun ; Lee, Sang-Yeol ; Kim, Eui-Jung ; Hong, Jin-Pyo ; Oh, Kang-Seob ; Woo, Jong-Min ; Kim, Seonwoo ; Park, Joo-Eon ; Yu, Bum-Hee</creatorcontrib><description>Abstract Somatic symptoms are often important in the treatment of major depressive disorder (MDD). The aim of this open-labeled trial was to examine the efficacy of mirtazapine for the treatment of MDD with clinically significant somatic symptoms, as compared with venlafaxine. A total of 126 patients with MDD (score ≥ 18 on the Hamilton Rating Scale for Depression-17) were included in both the intent-to-treat ( n = 73 in the mirtazapine group and n = 53 in the venlafaxine group) and completer analysis ( n = 51 and n = 37, respectively). After treatment, both treatment groups showed similar improvements in depressive symptoms. Repeated measures analysis of variance for the intent-to-treat population revealed that there were no significant differences in mean change of the Symptom Check List-90-Revised (SCL-90-R) somatization subscores between the two groups. For completers, there was a significant time × treatment interaction in the SCL-90-R somatization subscores, but the differences between the two groups at endpoint did not reach statistical significance in post-hoc analysis. In conclusion, this study suggests that overall efficacies of mirtazapine and venlafaxine are similar for the treatment of overall symptoms in MDD, and both drugs may be useful for the treatment of somatic symptoms in MDD patients.</description><identifier>ISSN: 0165-1781</identifier><identifier>EISSN: 1872-7123</identifier><identifier>DOI: 10.1016/j.psychres.2008.06.021</identifier><identifier>PMID: 19695711</identifier><identifier>CODEN: PSRSDR</identifier><language>eng</language><publisher>Kidlington: Elsevier Ireland Ltd</publisher><subject>Adult ; Adult and adolescent clinical studies ; Analysis of Variance ; Antidepressive Agents, Second-Generation - therapeutic use ; Antidepressive Agents, Tricyclic - therapeutic use ; Biological and medical sciences ; Chi-Square Distribution ; Cyclohexanols - therapeutic use ; Depression ; Depressive Disorder, Major - complications ; Depressive Disorder, Major - drug therapy ; Double-Blind Method ; Female ; Humans ; Major depressive disorder ; Male ; Medical sciences ; Mianserin - analogs & derivatives ; Mianserin - therapeutic use ; Middle Aged ; Mirtazapine ; Mood disorders ; Neuropharmacology ; Pharmacology. Drug treatments ; Prospective Studies ; Psychiatric Status Rating Scales ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Severity of Illness Index ; Somatic symptom ; Somatosensory Disorders - drug therapy ; Somatosensory Disorders - etiology ; Treatment response ; Venlafaxine ; Venlafaxine Hydrochloride</subject><ispartof>Psychiatry research, 2009-09, Vol.169 (2), p.118-123</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2008 Elsevier Ireland Ltd</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-8997a453c3ae7f743bcf8605a4f7fa1fc36f1422733d070eda72ba1ce5c474953</citedby><cites>FETCH-LOGICAL-c451t-8997a453c3ae7f743bcf8605a4f7fa1fc36f1422733d070eda72ba1ce5c474953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165178108001893$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21975655$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19695711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kang, Eun-Ho</creatorcontrib><creatorcontrib>Lee, In-Soo</creatorcontrib><creatorcontrib>Chung, Sang-Keun</creatorcontrib><creatorcontrib>Lee, Sang-Yeol</creatorcontrib><creatorcontrib>Kim, Eui-Jung</creatorcontrib><creatorcontrib>Hong, Jin-Pyo</creatorcontrib><creatorcontrib>Oh, Kang-Seob</creatorcontrib><creatorcontrib>Woo, Jong-Min</creatorcontrib><creatorcontrib>Kim, Seonwoo</creatorcontrib><creatorcontrib>Park, Joo-Eon</creatorcontrib><creatorcontrib>Yu, Bum-Hee</creatorcontrib><title>Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial</title><title>Psychiatry research</title><addtitle>Psychiatry Res</addtitle><description>Abstract Somatic symptoms are often important in the treatment of major depressive disorder (MDD). The aim of this open-labeled trial was to examine the efficacy of mirtazapine for the treatment of MDD with clinically significant somatic symptoms, as compared with venlafaxine. A total of 126 patients with MDD (score ≥ 18 on the Hamilton Rating Scale for Depression-17) were included in both the intent-to-treat ( n = 73 in the mirtazapine group and n = 53 in the venlafaxine group) and completer analysis ( n = 51 and n = 37, respectively). After treatment, both treatment groups showed similar improvements in depressive symptoms. Repeated measures analysis of variance for the intent-to-treat population revealed that there were no significant differences in mean change of the Symptom Check List-90-Revised (SCL-90-R) somatization subscores between the two groups. For completers, there was a significant time × treatment interaction in the SCL-90-R somatization subscores, but the differences between the two groups at endpoint did not reach statistical significance in post-hoc analysis. In conclusion, this study suggests that overall efficacies of mirtazapine and venlafaxine are similar for the treatment of overall symptoms in MDD, and both drugs may be useful for the treatment of somatic symptoms in MDD patients.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Analysis of Variance</subject><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>Antidepressive Agents, Tricyclic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chi-Square Distribution</subject><subject>Cyclohexanols - therapeutic use</subject><subject>Depression</subject><subject>Depressive Disorder, Major - complications</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Major depressive disorder</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mianserin - analogs & derivatives</subject><subject>Mianserin - therapeutic use</subject><subject>Middle Aged</subject><subject>Mirtazapine</subject><subject>Mood disorders</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Severity of Illness Index</subject><subject>Somatic symptom</subject><subject>Somatosensory Disorders - drug therapy</subject><subject>Somatosensory Disorders - etiology</subject><subject>Treatment response</subject><subject>Venlafaxine</subject><subject>Venlafaxine Hydrochloride</subject><issn>0165-1781</issn><issn>1872-7123</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks9u1DAQxiMEoqXwCpUvcCKLHSdxwgG1qvgnFXEAztasPdZ6SeLg8S5sn4JHxtEuIHHhNNLo982Mvm-K4lLwleCifbFdzXQwm4i0qjjvVrxd8UrcK85Fp6pSiUreL84z2JRCdeKseES05Twjff-wOBN92zdKiPPi5wcfE9zB7Cdke4y0o1ymARz8WFouRJY2yFJESCNOiQXHKIyQvGF0GOcURmJAFIyHhJZ992nDRthmncU530d-j8x6CtFifMmuWYTJhtHfoX3OwoxTOcAahyxN0cPwuHjgYCB8cqoXxZc3rz_fvCtvP759f3N9W5q6Eans-l5B3UgjAZVTtVwb17W8gdopB8IZ2TpRV5WS0nLF0YKq1iAMNqZWdd_Ii-LZce4cw7cdUtKjJ4PDABOGHelWtbKrhMhgewRNDEQRnZ6jHyEetOB6yUJv9e8s9JKF5q3ORmfh5WnDbj2i_Ss7mZ-BpycAyMDgsjHG0x8uZ6WatllOvTpymP3Ye4yajMfJoPURTdI2-P_f8uqfEWbwk89bv-IBaRt2ccpua6Gp0lx_Wj5neRzecS66XspfphLEDg</recordid><startdate>20090930</startdate><enddate>20090930</enddate><creator>Kang, Eun-Ho</creator><creator>Lee, In-Soo</creator><creator>Chung, Sang-Keun</creator><creator>Lee, Sang-Yeol</creator><creator>Kim, Eui-Jung</creator><creator>Hong, Jin-Pyo</creator><creator>Oh, Kang-Seob</creator><creator>Woo, Jong-Min</creator><creator>Kim, Seonwoo</creator><creator>Park, Joo-Eon</creator><creator>Yu, Bum-Hee</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090930</creationdate><title>Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial</title><author>Kang, Eun-Ho ; Lee, In-Soo ; Chung, Sang-Keun ; Lee, Sang-Yeol ; Kim, Eui-Jung ; Hong, Jin-Pyo ; Oh, Kang-Seob ; Woo, Jong-Min ; Kim, Seonwoo ; Park, Joo-Eon ; Yu, Bum-Hee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-8997a453c3ae7f743bcf8605a4f7fa1fc36f1422733d070eda72ba1ce5c474953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Analysis of Variance</topic><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>Antidepressive Agents, Tricyclic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chi-Square Distribution</topic><topic>Cyclohexanols - therapeutic use</topic><topic>Depression</topic><topic>Depressive Disorder, Major - complications</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Major depressive disorder</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mianserin - analogs & derivatives</topic><topic>Mianserin - therapeutic use</topic><topic>Middle Aged</topic><topic>Mirtazapine</topic><topic>Mood disorders</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Severity of Illness Index</topic><topic>Somatic symptom</topic><topic>Somatosensory Disorders - drug therapy</topic><topic>Somatosensory Disorders - etiology</topic><topic>Treatment response</topic><topic>Venlafaxine</topic><topic>Venlafaxine Hydrochloride</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Eun-Ho</creatorcontrib><creatorcontrib>Lee, In-Soo</creatorcontrib><creatorcontrib>Chung, Sang-Keun</creatorcontrib><creatorcontrib>Lee, Sang-Yeol</creatorcontrib><creatorcontrib>Kim, Eui-Jung</creatorcontrib><creatorcontrib>Hong, Jin-Pyo</creatorcontrib><creatorcontrib>Oh, Kang-Seob</creatorcontrib><creatorcontrib>Woo, Jong-Min</creatorcontrib><creatorcontrib>Kim, Seonwoo</creatorcontrib><creatorcontrib>Park, Joo-Eon</creatorcontrib><creatorcontrib>Yu, Bum-Hee</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychiatry research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Eun-Ho</au><au>Lee, In-Soo</au><au>Chung, Sang-Keun</au><au>Lee, Sang-Yeol</au><au>Kim, Eui-Jung</au><au>Hong, Jin-Pyo</au><au>Oh, Kang-Seob</au><au>Woo, Jong-Min</au><au>Kim, Seonwoo</au><au>Park, Joo-Eon</au><au>Yu, Bum-Hee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial</atitle><jtitle>Psychiatry research</jtitle><addtitle>Psychiatry Res</addtitle><date>2009-09-30</date><risdate>2009</risdate><volume>169</volume><issue>2</issue><spage>118</spage><epage>123</epage><pages>118-123</pages><issn>0165-1781</issn><eissn>1872-7123</eissn><coden>PSRSDR</coden><abstract>Abstract Somatic symptoms are often important in the treatment of major depressive disorder (MDD). The aim of this open-labeled trial was to examine the efficacy of mirtazapine for the treatment of MDD with clinically significant somatic symptoms, as compared with venlafaxine. A total of 126 patients with MDD (score ≥ 18 on the Hamilton Rating Scale for Depression-17) were included in both the intent-to-treat ( n = 73 in the mirtazapine group and n = 53 in the venlafaxine group) and completer analysis ( n = 51 and n = 37, respectively). After treatment, both treatment groups showed similar improvements in depressive symptoms. Repeated measures analysis of variance for the intent-to-treat population revealed that there were no significant differences in mean change of the Symptom Check List-90-Revised (SCL-90-R) somatization subscores between the two groups. For completers, there was a significant time × treatment interaction in the SCL-90-R somatization subscores, but the differences between the two groups at endpoint did not reach statistical significance in post-hoc analysis. In conclusion, this study suggests that overall efficacies of mirtazapine and venlafaxine are similar for the treatment of overall symptoms in MDD, and both drugs may be useful for the treatment of somatic symptoms in MDD patients.</abstract><cop>Kidlington</cop><pub>Elsevier Ireland Ltd</pub><pmid>19695711</pmid><doi>10.1016/j.psychres.2008.06.021</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-1781 |
| ispartof | Psychiatry research, 2009-09, Vol.169 (2), p.118-123 |
| issn | 0165-1781 1872-7123 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67638211 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Adult and adolescent clinical studies Analysis of Variance Antidepressive Agents, Second-Generation - therapeutic use Antidepressive Agents, Tricyclic - therapeutic use Biological and medical sciences Chi-Square Distribution Cyclohexanols - therapeutic use Depression Depressive Disorder, Major - complications Depressive Disorder, Major - drug therapy Double-Blind Method Female Humans Major depressive disorder Male Medical sciences Mianserin - analogs & derivatives Mianserin - therapeutic use Middle Aged Mirtazapine Mood disorders Neuropharmacology Pharmacology. Drug treatments Prospective Studies Psychiatric Status Rating Scales Psychiatry Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Severity of Illness Index Somatic symptom Somatosensory Disorders - drug therapy Somatosensory Disorders - etiology Treatment response Venlafaxine Venlafaxine Hydrochloride |
| title | Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T07%3A43%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mirtazapine%20versus%20venlafaxine%20for%20the%20treatment%20of%20somatic%20symptoms%20associated%20with%20major%20depressive%20disorder:%20A%20randomized,%20open-labeled%20trial&rft.jtitle=Psychiatry%20research&rft.au=Kang,%20Eun-Ho&rft.date=2009-09-30&rft.volume=169&rft.issue=2&rft.spage=118&rft.epage=123&rft.pages=118-123&rft.issn=0165-1781&rft.eissn=1872-7123&rft.coden=PSRSDR&rft_id=info:doi/10.1016/j.psychres.2008.06.021&rft_dat=%3Cproquest_cross%3E67638211%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67638211&rft_id=info:pmid/19695711&rft_els_id=S0165178108001893&rfr_iscdi=true |